Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus GC and Surgery for Oligometastatic Urothelial Carcinoma
NCT04570410Phase 2Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in urothelial carcinoma (UC), sponsored by Jiangsu Provincial People's Hospital. Started Dec 2020; status: completed.
02
Drugs
tislelizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04570410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570410.